Back to News
Market Impact: 0.2

ETF Fundamental Report for SPYV

SPYVNDAQ
Company FundamentalsAnalyst InsightsDerivatives & Volatility
ETF Fundamental Report for SPYV

Validea's fundamental report on the SPDR Portfolio S & P 500 Value ETF (SPYV) characterizes it as a Large-Cap Low Volatility ETF, scoring 85 for low volatility and 62 for value exposure. The fund's portfolio is predominantly allocated to the Financial sector and the Biotechnology & Drugs industry, offering investors a clear profile of its factor tilts and sector concentrations.

Analysis

The SPDR Portfolio S&P 500 Value ETF (SPYV) is fundamentally profiled as a Large-Cap Low Volatility fund, a characterization strongly substantiated by its high Low Volatility factor score of 85 out of 99. The ETF also presents a significant value tilt with a score of 62, consistent with its name. However, its exposure to other key factors is notably weaker, with a neutral Quality score of 55 and a particularly low Momentum score of 32, indicating it is not positioned to capture market trends. Portfolio construction reveals a heavy concentration in the Financial sector, while its single largest industry exposure is in Biotechnology & Drugs. This specific combination of factor exposures and sector concentrations provides a clear profile for investors seeking defensive positioning with a value orientation, rather than growth or momentum.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

NDAQ0.00
SPYV0.00

Key Decisions for Investors

  • Investors seeking to lower portfolio volatility or add a defensive large-cap position should consider SPYV, given its high low-volatility score of 85.
  • Be aware that the fund's very low momentum score of 32 suggests it is likely to underperform in strongly trending, momentum-driven markets.
  • The heavy concentration in the Financial sector and a specific overweight in Biotechnology & Drugs means an investor's view on these segments is critical to assessing the fund's suitability and potential performance.